ASLAN Pharmaceuticals Pte Ltd

161 articles with ASLAN Pharmaceuticals Pte Ltd

• ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003

  7/13/2021

  ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that it has closed a secured loan facility provided by K2 HealthVentures.

• ASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies Virtual Healthcare Conference

  5/25/2021

  ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, 1 June, 2021 at 11:30am ET. The conference will be held from 1-4 June 2021.

• ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/11/2021

  - Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021  - Phase 2b clinical trial for ASLAN004 expected to initiate in the second half of 2021

• ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology

  5/5/2021

  ASLAN will give a poster presentation of new data from its Single Ascending Dose study of ASLAN004, during the virtual event on 6 May, 2021

• ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

  4/22/2021

  ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its clinical development activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said : “ASLAN made significant progress in the fourth quart

• ASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent Director

  3/18/2021

  ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director.

• ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares

  3/3/2021

  ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced the pricing of an underwritten public offering of 15,000,000 American Depositary Shares representing 75,000,000 ordinary shares at a price to the public of $4.00 per ADS.

• ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares - Mar 01, 2021

  3/1/2021

  ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that it has commenced an underwritten public offering of $60.0 million of its American Depositary Shares representing ordinary shares.

• ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis

  3/1/2021

  74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90

• ASLAN Pharmaceuticals Announces $18 Million Private Placement

  2/25/2021

  ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a securities purchase agreement to raise gross proceeds of approximately $18 million resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital

• ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director

  2/18/2021

  ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced the appointment of Neil Graham, MBBS, MD, MPH as an independent director.

• New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class

  1/26/2021

  ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that new data from a study conducted by University of Liverpool, UK, published in the Toxicology in Vitro Journal, demonstrates that, out of a panel of six dihydroorotate dehydrogenase (DHODH) inhibitors tested,

• ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

  1/11/2021

  ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels

• ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference

  11/19/2020

  ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32 nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. A replay of the pre-recorded fireside chat will be available fr

• ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/9/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced financial results for the third quarter ended September 30, 2020 and provided an update on its clinical activities.

• 

  BioSpace Global Roundup, Oct. 22

  10/22/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial

  10/22/2020

  --     ASLAN has initiated recruitment of patients into third dos e cohort at sites in the US, Australia and Singapore following successful safety review of second cohort --    ASLAN004 found to be well tolerated at 400mg dose , third cohort will test 600mg dose

• ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

  10/16/2020

  Withnanomolar potency against SARS-CoV-2, ASLAN003 is also being assessed for its potential as a novel therapeutic for COVID-19 and other viruses

• ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

  9/21/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis patients.

• ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/10/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference.